QurAlis

Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization rights to a portfolio of UNC13A-targeting compounds from QurAlis, a biopharmaceutical company based in the U.S. The portfolio includes the antisense oligonucleotide (ASO) QRL-204, which is considered a potential best-in-class candidate for treating neurodegenerative diseases…